NVAX Novavax Inc

Price (delayed)

$176.00

Market cap

$13B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.27

Enterprise value

$12.82B

Sector: Healthcare
Industry: Biotechnology

Novavax, Inc. is an American vaccine development company headquartered in Gaithersburg, Maryland, with additional facilities in Rockville, Maryland and Uppsala, Sweden. As of 2020, it has an ongoing Phase III ...

Highlights

The revenue has soared by 132% from the previous quarter
NVAX's gross profit has soared by 132% QoQ
Novavax's net income has plunged by 53% from the previous quarter
NVAX's quick ratio is down by 47% year-on-year and by 25% since the previous quarter

Key stats

What are the main financial stats of NVAX
Market
Shares outstanding
73.86M
Market cap
$13B
Enterprise value
$12.82B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
17.86
Price to sales (P/S)
21.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.95
Earnings
Revenue
$475.6M
EBIT
-$403.11M
EBITDA
-$152.37M
Free cash flow
-$97.16M
Per share
EPS
-$7.27
Free cash flow per share
-$1.69
Book value per share
$9.85
Revenue per share
$8.26
TBVPS
$25.04
Balance sheet
Total assets
$1.58B
Total liabilities
$955.27M
Debt
$467.98M
Equity
$627.21M
Working capital
$668.53M
Liquidity
Debt to equity
0.75
Current ratio
2.15
Quick ratio
1.84
Net debt/EBITDA
1.19
Margins
EBITDA margin
-32%
Gross margin
100%
Net margin
-87.9%
Operating margin
-87.6%
Efficiency
Return on assets
-44.2%
Return on equity
-187.1%
Return on invested capital
-78.1%
Return on capital employed
-40.2%
Return on sales
-84.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NVAX stock price

How has the Novavax stock price performed over time
Intraday
2.02%
1 week
-25.72%
1 month
2.46%
1 year
869.7%
YTD
57.83%
QTD
-2.93%

Financial performance

How have Novavax's revenue and profit performed over time
Revenue
$475.6M
Gross profit
$475.6M
Operating income
-$416.72M
Net income
-$418.26M
Gross margin
100%
Net margin
-87.9%
The revenue has soared by 132% from the previous quarter
NVAX's gross profit has soared by 132% QoQ
Novavax's net margin has surged by 88% YoY and by 34% QoQ
The operating margin has soared by 86% year-on-year and by 32% since the previous quarter

Growth

What is Novavax's growth rate over time

Valuation

What is Novavax stock price valuation
P/E
N/A
P/B
17.86
P/S
21.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.95
Novavax's EPS has decreased by 41% QoQ and by 32% YoY
The revenue has soared by 132% from the previous quarter
NVAX's P/S is 52% below its last 4 quarters average of 44.2 and 19% below its 5-year quarterly average of 26.2

Efficiency

How efficient is Novavax business performance
The ROIC has plunged by 119% YoY and by 30% from the previous quarter
Novavax's return on sales has surged by 87% YoY and by 33% QoQ
Novavax's return on equity has surged by 86% QoQ
NVAX's return on assets is up by 38% year-on-year and by 3.7% since the previous quarter

Dividends

What is NVAX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NVAX.

Financial health

How did Novavax financials performed over time
Novavax's total assets is 66% higher than its total liabilities
The total liabilities has soared by 166% year-on-year and by 50% since the previous quarter
Novavax's total assets has surged by 68% QoQ
Novavax's debt is 25% lower than its equity
NVAX's debt to equity has surged by 144% year-on-year but it has dropped by 82% since the previous quarter
Novavax's debt has increased by 46% YoY and by 6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.